The prevalence of overweight and obesity in the United States has dramatically increased. Obesity clusters with a variety of hemodynamic and metabolic disturbances that increase the risk of cardiovascular disease. In this study we evaluated whether overweight subjects with hypertension also manifest hemodynamic and metabolic abnormalities compared with individuals of normal weight.
T he prevalence of obesity in industrialized countries has increased dramatically during the last 10 years. Currently 30% to 35% of adults are obese and more than 30% are overweight. 1 According to current estimates ϳ75% and ϳ65% of cases of hypertension in men and women respectively are attributable to overweight or obesity. 2 Measures of obesity such as body mass index (BMI) and waist-to-hip ratio have been shown to relate strongly to blood pressure (BP). [3] [4] [5] [6] Individuals who are obese manifest a cluster of metabolic and hormonal abnormalities, including insulin resistance, hyperinsulinemia, hypertriglyceridemia, increased sympathetic nervous system activity, and abnormalities in the hypothalamic-pituitary-adrenal axis, which increase the risk of cardiovascular diseases and events. [7] [8] [9] [10] [11] Less well established is whether overweight also clusters with similar hormonal and metabolic disturbances.
This study was undertaken to evaluate whether overweight subjects manifest hemodynamic and metabolic abnormalities and evidence of cardiovascular and renal damage when compared with lean individuals. To this end, we retrospectively evaluated the relationship of BMI with BP, insulin sensitivity, lipid profile, and markers of vascular and kidney damage such as IMT and UAE in a cohort of patients with essential hypertension.
Methods

Study Design and Patient Population
These studies were approved by the Human Research Committee of the Spedali Riuniti of Livorno, Italy, and all subjects gave informed consent. A total of 129 patients with essential hypertension and 41 normotensive healthy subjects were included in this study. The clinical characteristics of the subjects are shown in Table 1 . Subjects with a BMI Ն30, creatinine clearance Ͻ80 mL/min/1.73 m 2 , and abnormal urinalysis were excluded. Hypertension was defined as an average BP Ն140/90 mm Hg during three subsequent clinic visits. Measurements of BP were taken three times after the subjects had been sitting for at least 5 min in a quiet room, and the average of these three measurements was recorded. A diagnosis of secondary hypertension was adequately excluded by the findings of normal routine blood analysis, urinalysis, electrocardiogram, and when clinically indicated by chest X-rays, and by normal urinary metanephrines, plasma aldosterone, diethylenetriamine pentaacetic acid technetium scan (DTPA) and renal angiogram. Hypertensive patients and control subjects with a family history of diabetes mellitus, as well as women of childbearing potential were excluded. None of the hypertensive patients was receiving antihypertensive treatment at the time of the study. Of the hypertensive patients, 89 had never received antihypertensive drug treatment before enrollment; the remaining 41 patients discontinued their antihypertensive drugs at least 4 weeks before the study. Among the pretreated hypertensive individuals, 23 were overweight and 18 were of normal weight. Among the previously treated hypertensive patients, 15 had been treated with a calcium channel blocker (eight subjects of normal weight and seven overweight), 14 with an angiotensin-converting enzyme inhibitor (seven of normal weight and seven overweight), and the remaining 12 subjects with ␤-blockers or diuretics or both (seven of normal weight and five overweight). All subjects remained on their usual diets.
After meeting the inclusion criteria, all subjects were instructed to collect all urine for 24 h on three different occasions, 1 week apart, for the determination of UAE and creatinine clearance. The reported values are the average of these three measurements.
Baseline Measurements and Oral Glucose Tolerance Test
All hypertensive and normotensive subjects underwent an oral glucose tolerance test (OGTT). Subjects came to the outpatient clinic after fasting overnight for 12 to 14 h. After subjects rested for 30 min in the supine position and underwent placement of venous catheters in an antecubital vein of forearm, BP was measured at least three times and blood samples were drawn. Subjects received an oral load of 75 g glucose, and blood was drawn for measurement of plasma glucose and insulin before and 30, 60, 90, and 120 min after the glucose load.
Biochemical Assays
Total serum cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, and apolipoprotein A and B were measured immediately after sampling. Total serum cholesterol, HDL, and triglycerides were measured by enzymatic methods. The concentration of LDL and VLDL was calculated with the formula of Fridewald et al. 12 Apolipopro- AUC ϭ area-under-the curve; BMI ϭ body mass index; BP ϭ blood pressure; HDL ϭ high-density lipoptoteins; IMT ϭ intima-media thickness; LDL ϭ low-density lipoproteins; Lp (a) ϭ lipoprotein (a); UAE ϭ urinary albumin excretion. Data are expressed as mean Ϯ SEM.
tein A and B were measured by nephelometry with antiserum and standard reagents from Behringwerke AG (Marburg, Germany). Plasma for the assay of lipoprotein (a) [Lp(a)] and insulin was frozen and stored at Ϫ30°C and measured within 15 days. Lp(a) was measured by enzyme-immunoassay (Immunozyme Lp(a), Immuno, Wien), and plasma insulin by radioimmunoassay. Creatinine was measured by standard methods. The albumin concentration in the urine was measured by an immunoturbidometric method. The intra-assay coefficient of variation for urine albumin was 1.2% and the interassay coefficient 4.3%.
The BMI was calculated as weight (in kilograms) divided by the height in meters squared.
Ambulatory BP Monitoring
Ambulatory BP monitoring (ABPM) measurements were made within 3 days from the baseline evaluation and OGTT. The ABPM was measured by the Takeda A and D model TM-2420 (Osaka, Japan). In brief, readings were taken from the left arm every 20 min from 7 AM to 23 PM (daytime period) and every 30 min from 23 PM to 7 AM (night-time period). All patients underwent ABPM as outpatients during a working day and without any particular change in their usual habits and diet. Subjects kept a diary to report bedtime and any significant episode that might have occurred during the recording (eg, physical or emotional stress, or nocturnal awakenings and their causes). The time for awakening was 7 AM by an alarm.
From the 24-h BP profile we calculated 24-h average systolic, 24-h average diastolic, and daytime and nighttime average systolic and diastolic BP.
Carotid Intima Thickness
To determine the relationship between BMI and markers of vascular injury, carotid intima thickness (IMT) was measured in all study subjects. The IMT was measured within 3 days from the baseline evaluation and OGTT, using B-mode ultrasound imaging (model AU 590, EsaOteBiomedica, Milano, Italy) according to published guidelines. 13 Patients were kept in supine position with the head slightly hyperextended. The thickness of the far wall of the common carotid artery was measured over several cardiac cycles by a two-dimensional method at end-diastole and avoiding segments with discrete atheromas. Six separate measurements were made of the right carotid and six of the left carotid artery. To obtain a bidimensional view of the arteries, three measurements on each side were made along the antero-posterior (AP) axis and three measurements along the latero-medial (LM) axis. In longitudinal artery images two main interfaces, the lumen-intima and the media-adventitia interfaces of the far wall, were measured 10 mm below the proximal origin of the bulb. Data are reported as the means of the six measurements along the AP axis and six measurements along the LM axis. The mean IMT of the 12 sites (APϩLM) was used to estimate the extent and severity of carotid atherosclerosis. The radiologists who measured the carotid intima thickness were unaware of the clinical and biochemical characteristics of the subjects studied and of the fact that comparisons were being stratified according to BMI. The coefficient of variation for IMT was 15.56.
The sample size required to detect group differences in IMT of 0.010 mm was computed. With a power of 80% and a two-sided ␣ level of 0.05, we needed 111 subjects per group to detect a difference of this magnitude.
Statistical Analyses
Data were analyzed by the Student t test to determine differences between hypertensive and normotensive subjects, and by the Kolmogorov-Smirnov test for comparison of nonparametric parameters, namely, UAE, insulin AUC, and lipoprotein(a). For bivariate analysis, the correlations between each pairs of continuous variables were analyzed using Pearson correlation tests. Significantly correlated pairs of variables with a P Յ .050 in the bivariate analysis were entered into the linear regression analysis to estimate ␤-coefficients with P values of the independent variables, including age, UAE, insulin AUC, glucose AUC, lipoproteins, BP, and IMT. Dependent variables for the linear regression were BMI and office mean arterial pressure. Table 1 lists the clinical characteristics of hypertensive and normotensive healthy subjects in the study. Age, sex, and BMI did not differ between hypertensive and control subjects. Hypertensive individuals showed higher levels of serum triglycerides, Lp(a), and insulin area-under-the-curve (AUC) as well as lower levels of HDL cholesterol than normotensive healthy subjects. Hypertensive individuals also had more evidence of end-organ damage than normotensive subjects, as evident from significantly greater carotid artery thickness and urine albumin excretion. Table 2 shows comparisons between 41 overweight hypertensive subjects and 81 patients with normal weight. Overweight hypertensive subjects were older and had higher levels of serum triglycerides, LDL cholesterol, glucose-AUC, insulin AUC and lower levels of HDL cholesterol than hypertensive subjects with normal body weight ( Table 2 ). In addition the overweight hypertensive subjects had greater IMT and urine albumin excretion values than hypertensive subjects with normal BMI.
Results
Office and daytime ambulatory BP levels did not differ between hypertensive patients with normal weight and those who were overweight. However, night-time systolic BP was significantly higher among overweight hypertensive patients than among those with normal body weight ( Table 3 ). The fall in systolic and diastolic BP during the night-time compared with the daytime was lower among overweight hypertensive subjects than among those of normal weight.
We did not analyze normotensive overweight subjects separately from those with normal weight, as only nine normotensive subjects had normal body weight and the rest were overweight.
A significant correlation was observed between BMI and UAE among both normotensive (r ϭ 0.56; P Ͻ . 0005) and hypertensive subjects (r ϭ 0.34, P ϭ . 0001). The BMI was also significantly correlated with 24-h (r ϭ 0.30; P ϭ . 0032) and night-time systolic (0.35; P ϭ . 0008) and diastolic (r ϭ 0.20; P ϭ .05) BP in hypertensive subjects. The BMI was significantly correlated with insulin AUC, in both hypertensive (0.43; P ϭ . 0001) and normotensive subjects (0.4; P Ͻ . 05), and with glucose AUC among hypertensive subjects (r ϭ 0.29, P ϭ .0097) but not among their normotensive counterparts. The BMI was significantly correlated with total cholesterol (0.24, P ϭ . 0058), triglycerides (0.35, P ϭ . 0001), HLD cholesterol (r ϭ 0.24, P ϭ . 0057), and LDL cholesterol (r ϭ 0.22, P ϭ . 012) among hypertensive but not among normotensive subjects (Table 4) . However multiple regression analyses using BMI as the dependent variable showed a significant relation only with UAE in hypertensive but not in normotensive subjects (P Ͻ .0392) ( Table 4) . Multiple regression analyses using mean arterial pressure as the dependent variable showed a significant relations with UAE (P Ͻ . 01), insulin AUC (P Ͻ . 01), and BMI (P Ͻ . 01) in hypertensive but not in normotensive subjects.
Discussion
The association among obesity, hypertension, insulin resistance, and dyslipidemia is well established. In these studies we have shown that overweight hypertensive and normotensive subjects also manifest a cluster of cardiovascular risk factors including lipoprotein abnormalities and insulin resistance. These abnormalities were more pronounced in hypertensive than in normotensive individu- Abbreviations as in Table 1 . Data are expressed as mean Ϯ SEM; * P Ͻ.01 compared with normal weight subjects; † P Ͻ.05 compared with normal weight subjects. als. Increased body weight was associated with increased urine albumin excretion even in the absence of hypertension, whereas increased carotid IMT was present in overweight hypertensive individuals but not in those of normal weight. These studies have also shown that overweight hypertensive subjects have office and 24-h ambulatory BP values that are similar to values in patients of normal weight. However, night-time systolic BP was significantly greater among overweight patients than among those of normal weight. In addition, the night-time fall in BP was lower among overweight hypertensive subjects than among those of normal weight. In a cohort of 3216 subjects, Kotsis et al 14 observed significant correlations between BMI and 24-h daytime and night-time systolic BP, as well as a higher incidence of nondipping status in obese individuals. Because we did not systematically perform assessment of sleep-disordered breathing, we cannot rule out the possibility that this may account for higher nocturnal BP among overweight patients.
Abnormalities of glucose, insulin, and lipoprotein metabolism are common in patients with hypertension and can be discerned even in normotensive first-degree relatives of hypertensive patients. 15 Insulin resistance and hyperinsulinemia are more severe and more closely associated with hypertension in obese than in nonobese subjects. 16, 17 Insulin resistance is common among obese subjects and is caused by a defect in the ability of insulin to stimulate the metabolism of glucose by muscle and its storage as glycogen. These metabolic abnormalities may play a part in both the pathogenesis and the complications of hypertension in many patients. Reaven et al 7 have hypothesized that the metabolic abnormalities are linked to the hypertension by a pathophysiologic process that involves the sympathoadrenal system and exerts both prohypertensive and atherogenic effects. According to this hypothesis, hyperinsulinemia, a consequence of insulin resistance, stimulates the sympathetic nervous system, increasing sympathetically mediated thermogenesis and re-establishing energy balance. The increase in sympathetic nervous system activity, however, also contributes to hypertension by stimulating the heart, increasing vasoconstriction, and causing renal sodium retention. Obesity-related hypertension may be the unwanted byproduct of mechanisms to restore energy balance and stabilize body weight.
The notion that sympathetic nerve activity is pathogenic is based on observations that short-term insulin infusion stimulates sympathetic nerve activity in lean subjects, and that obesity (a state characterized by hyperinsulinemia) is associated with sustained sympathetic activation. 18 In a cohort followed as part of the Normative Aging Study, sympathetic nervous system activity, as assessed by 24-h urinary excretion of norepinephrine, was elevated in subjects with hyperinsulinemia and correlated with BMI. 19 In the current study we measured IMT as a marker of atherosclerosis. Epidemiologic studies have demonstrated an association of carotid IMT with cardiovascular risk factors 20, 21 and with angiographically determined presence of coronary artery disease. 22, 23 Overweight hypertensive patients manifested significantly greater IMT indicating a greater degree of vascular damage than hypertensive patients with normal weight and normotensive subjects Irace et al 24 observed increased carotid atherosclerosis among patients with hypertension and the metabolic syndrome compared with subjects with the metabolic syndrome but without hypertension. We observed no effect of overweight on IMT independent of BP, but the group of normotensive subjects was not adequately powered to detect IMT differences of 0.1 mm.
Subjects with increased BMI manifested greater amount of urine albumin excretion. The relationship between BMI and UAE persisted even after correcting for other confounding factors. Microalbuminuria correlates with progressive kidney disease as well as with cardiovascular disease and it can be used as a marker and predictor of kidney and cardiovascular damage. 25 Microalbuminuria clusters with other cardiovascular risk factors such as dislipidemia and insulin resistance, 26 with abnormalities in circadian BP vari- Abbreviations as in Table 4 .
ability, 25 and with evidence of cardiovascular damage such as increased carotid media-intima thickness.
Chen et al 27 observed a significant correlation between abdominal waist circumference, degree of microalbuminuria, and decline of glomerular filtration rate. Iseki et al 28 observed a statistical association between BMI and incidence of end-stage renal disease in a Japanese population. In obese individuals several renal abnormalities have been described, including glomerulomegaly and focal and segmental glomerulosclerosis. 29 Clinically these patients may present with proteinuria, sometimes in the nephritic range, and progressive renal insufficiency in approximately 50% of patients.
It is important to underscore that our studies do not prove a cause-and-effect relationship between BMI and the described hemodynamic and metabolic abnormalities. Indeed, although simple regression analyses in hypertensive subjects showed significant correlations among BMI and 24-h and night-time systolic and diastolic BP, insulin and glucose AUC, total cholesterol, triglycerides, HLD cholesterol, LDL cholesterol, and IMT, multiple regression analyses using BMI as the dependent variable showed a significant relationship only with UAE.
In summary these studies have shown that increased body weight clusters with a variety of hemodynamic and metabolic abnormalities in hypertensive subjects. However multiple regression analyses showed a significant correlation only between BMI and UAE, a marker and predictor of cardiovascular and renal disease.
